QGEN Stock Analysis: Buy, Sell, or Hold?
QGEN - QIAGEN N.V.
$39.40
0.33 (0.84%)
▲
5d:
-0.23%
30d:
-20.88%
90d:
-13.16%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When QGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: QGEN appears deeply undervalued. Market expects -7.1% annual earnings decline despite 22% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: QGEN appears deeply undervalued. Market expects -7.1% annual earnings decline despite 22% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$68.70
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$42.65
7.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: QGEN is currently trading at $39.40, which is considered oversold relative to its 30-day fair value range of $40.00 to $47.55. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.1) compared to its historical average (17.7). Remarkably, the market is currently pricing in an annual earnings decline of 7.1% over the next few years. This pessimistic expectation contrasts with the company's recent 21.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, QGEN is in a uptrend. The price is currently testing key support at $38.80. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $55.46 (+42.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, QGEN is in a uptrend. The price is currently testing key support at $38.80. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $55.46 (+42.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$40.00 -
$47.55
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.0% below Wall St target ($55.46)
Fair Price Analysis
30-Day Fair Range
$40.00 -
$47.55
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$38.80
Resistance Level
$41.56
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.14
Wall Street Target
$55.46
(+42.0%)
Revenue Growth (YoY)
3.7%
Earnings Growth (YoY)
21.9%
Profit Margin
20.3%
Valuation Discount vs History
-7.1% cheaper
PE vs Historical
14.1 vs 17.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.1%
(market-implied from PE analysis)
1-Year Target
$36.30
(-7%)
2-Year Target
$33.72
(-14%)
3-Year Target
$31.32
(-20%)
3-Yr Target (if PE normalizes)
(PE: 14→18)
$39.22
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 10.1%)
$82.65
(+112%)
Base:
(SPY PE: 14.1, Growth: 10.1%)
$52.16
(+34%)
Bear:
(PE: 12.0, Growth: 10.1%)
$44.34
(+14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 19.57 | Current EPS (TTM): $2.04
Bull Case
$59.52
(+51%)
Analyst growth 35.5%, PE expands to 21.5
Base Case
$54.11
(+37%)
Market implied 35.5%, PE stable at 19.6
Bear Case
$27.15
(-31%)
Severe decline -20.0%, PE contracts to 16.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.1 to 17.7
Stabilization Target:
$48.91
(+25.2%)
PE Expansion Potential:
+25.2%
Share & Embed Analysis
Last updated: March 30, 2026 12:11 PM ET
Data refreshes hourly during market hours. Next update: 1:11 PM
Data refreshes hourly during market hours. Next update: 1:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$664 | 58 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$265 | 58 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$133 | 56 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 60 HOLD |
